First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

February 16, 2023

Study Completion Date

February 16, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

IBI101

0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days

DRUG

IBI101

1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days

DRUG

Sintilimab

200mg iv infusion day 1 of every 21 days

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03758001 - First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter